

filing on November 9, 1999. A decision must be rendered prior to this application
being allowed or proceeding on appeal.

In the Claims

10. (twice amended) A method for inhibiting human C5b-9 complex assembly comprising administering to a patient in need thereof an effective amount of a composition comprising a peptidomimetic selected from the group consisting of proteins, peptides, nucleic acids, and small molecules having the structure and function of human CD59 amino acid residues 42-58, and binding specifically to amino acid residues 359-384 of human C9.

11. (twice amended) The method of claim 10, wherein the peptidomimetic is [selected from the group consisting of proteins, peptides, nucleic acids, and] a small [molecules] molecule which [bind] binds specifically to amino acids 359 to 384 of human C9.

12. (amended) The method of claim [11] 10, wherein the protein is an antibody.

13. (twice amended) The method of claim [11] 10, wherein the protein is a chimeric peptide which includes the amino acids 42 to 58 of the human sequence of CD59.

14. (twice amended) The method of claim [11] 10, wherein the peptide is a covalently cyclized [peptides] peptide comprising human CD59 amino acid residues 42 to 58.